NEWS
Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2024 Financial and Operational Results
Bioceres Crop Solutions (NASDAQ: BIOX) reported its fiscal fourth quarter and full-year 2024 results. Key highlights include:
- FY24 total revenues of $464.8 million, up 11% year-over-year
- FY24 GAAP net income of $6.2 million
- FY24 adjusted EBITDA of $81.4 million
- Q4 revenues of $124.0 million, up 18% year-over-year
- Q4 adjusted EBITDA of $19.9 million, nearly doubling from last year
Growth was driven by increases in HB4 sales, adjuvants, and biostimulants. The company received approval for HB4 Wheat cultivation in the United States, expanding its market potential. Despite challenging agricultural conditions, Bioceres maintained profitability and demonstrated resilience in its diversified technology portfolio.
- FY24 total revenues of $464.8 million, up 11% year-over-year
- FY24 GAAP net income of $6.2 million
- FY24 adjusted EBITDA of $81.4 million
- Q4 revenues of $124.0 million, up 18% year-over-year
- Q4 adjusted EBITDA of $19.9 million, nearly doubling from last year
Growth was driven by increases in HB4 sales, adjuvants, and biostimulants. The company received approval for HB4 Wheat cultivation in the United States, expanding its market potential. Despite challenging agricultural conditions, Bioceres maintained profitability and demonstrated resilience in its diversified technology portfolio.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment